Literature DB >> 2910513

Tumor and serum tamoxifen concentrations in the athymic nude mouse.

M W DeGregorio1, E Coronado, C K Osborne.   

Abstract

The athymic nude mouse has been used as an in vivo model for pharmacologic studies of the antiestrogen, tamoxifen. Serum and tumor tamoxifen and metabolite concentrations were examined during and after 100 and 1000 micrograms/day doses injected s.c. Tamoxifen and tamoxifen metabolites were quantitated by high-performance liquid chromatography. Tamoxifen was detected in tumors after a dose of 100 micrograms/day, although serum concentrations were not detected. At a dose of 1000 micrograms/day, tumor tamoxifen and its active metabolites were detected in high concentrations ranging up to greater than 6 mmol/g tissue. Serum tamoxifen metabolites were not detected at either dose. In summary, high doses of tamoxifen were required in the nude mouse to obtain clinically relevant serum concentrations, and significant tumor levels were achieved at doses that resulted in undetectable serum levels. The relationship between serum tamoxifen concentrations, tumor tamoxifen levels, and the biologic activity of the drug requires further study.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2910513     DOI: 10.1007/BF00273519

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  9 in total

1.  Clonal variation of MCF-7 breast cancer cells in vitro and in athymic nude mice.

Authors:  K Seibert; S M Shafie; T J Triche; J J Whang-Peng; S J O'Brien; J H Toney; K K Huff; M E Lippman
Journal:  Cancer Res       Date:  1983-05       Impact factor: 12.701

2.  Estrogen responsive proliferation of clonal human breast carcinoma cells in athymic mice.

Authors:  H D Soule; C M McGrath
Journal:  Cancer Lett       Date:  1980-08       Impact factor: 8.679

3.  Cell proliferation kinetics of MCF-7 human mammary carcinoma cells in culture and effects of tamoxifen on exponentially growing and plateau-phase cells.

Authors:  R L Sutherland; R E Hall; I W Taylor
Journal:  Cancer Res       Date:  1983-09       Impact factor: 12.701

4.  Clinical pharmacology of tamoxifen in patients with breast cancer: correlation with clinical data.

Authors:  C Fabian; L Sternson; M El-Serafi; L Cain; E Hearne
Journal:  Cancer       Date:  1981-08-15       Impact factor: 6.860

5.  Effects of tamoxifen on human breast cancer cell cycle kinetics: accumulation of cells in early G1 phase.

Authors:  C K Osborne; D H Boldt; G M Clark; J M Trent
Journal:  Cancer Res       Date:  1983-08       Impact factor: 12.701

6.  Serum tamoxifen concentrations in the athymic nude mouse after three methods of administration.

Authors:  M W DeGregorio; B J Wilbur; E Coronado; C K Osborne
Journal:  Cancer Chemother Pharmacol       Date:  1987       Impact factor: 3.333

7.  Effect of estrogens and antiestrogens on growth of human breast cancer cells in athymic nude mice.

Authors:  C K Osborne; K Hobbs; G M Clark
Journal:  Cancer Res       Date:  1985-02       Impact factor: 12.701

8.  Role of hormones in the growth and regression of human breast cancer cells (MCF-7) transplanted into athymic nude mice.

Authors:  S M Shafie; F H Grantham
Journal:  J Natl Cancer Inst       Date:  1981-07       Impact factor: 13.506

9.  Effect of tamoxifen on the receptor-positive T61 and the receptor-negative T60 human breast carcinomas grown in nude mice.

Authors:  N Brünner; M Spang-Thomsen; L Vindeløv; J Wolff; S A Engelholm
Journal:  Eur J Cancer Clin Oncol       Date:  1985-11
  9 in total
  6 in total

1.  Biomarker system for studying muscle, stem cells, and cancer in vivo.

Authors:  Koichi Nishijo; Tohru Hosoyama; Christopher R R Bjornson; Beverly S Schaffer; Suresh I Prajapati; Ali N Bahadur; Mark S Hansen; Mary C Blandford; Amanda T McCleish; Brian P Rubin; Jonathan A Epstein; Thomas A Rando; Mario R Capecchi; Charles Keller
Journal:  FASEB J       Date:  2009-03-30       Impact factor: 5.191

2.  Clonal tracing of Sox9+ liver progenitors in mouse oval cell injury.

Authors:  Branden D Tarlow; Milton J Finegold; Markus Grompe
Journal:  Hepatology       Date:  2014-05-28       Impact factor: 17.425

3.  Pax7 is back.

Authors:  Andrew S Brack
Journal:  Skelet Muscle       Date:  2014-12-14       Impact factor: 4.912

4.  Development of a novel molecular sensor for imaging estrogen receptor-coactivator protein-protein interactions.

Authors:  Madryn C Lake; Quang-Dé Nguyen; Simak Ali; Eric O Aboagye
Journal:  PLoS One       Date:  2012-08-28       Impact factor: 3.240

5.  Tamoxifen-elicited uterotrophy: cross-species and cross-ligand analysis of the gene expression program.

Authors:  Joshua C Kwekel; Agnes L Forgacs; Lyle D Burgoon; Kurt J Williams; Timothy R Zacharewski
Journal:  BMC Med Genomics       Date:  2009-04-28       Impact factor: 3.063

Review 6.  Advances in hepatic stem/progenitor cell biology.

Authors:  Stefaan Verhulst; Jan Best; Leo A van Grunsven; Laurent Dollé
Journal:  EXCLI J       Date:  2015-01-06       Impact factor: 4.068

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.